



US005856345A

# United States Patent [19]

[11] Patent Number: **5,856,345**

Doi et al.

[45] Date of Patent: **Jan. 5, 1999**

[54] **METHOD FOR STABILIZING PRANOPROFEN AND STABLE LIQUID PREPARATION OF PRANOPROFEN**

### FOREIGN PATENT DOCUMENTS

[75] Inventors: **Koji Doi**, Kobe; **Hisako Sawa**, Otsu; **Yoshie Ozaki**, Kobe; **Yoshiyuki Kimura**, Kakogawa, all of Japan

0 258 865	3/1988	European Pat. Off. .
0 471 084 A1	2/1992	European Pat. Off. .
2 839 752	5/1979	Germany .
2 007 091	5/1979	United Kingdom .
86/06629	11/1986	WIPO .
92/20376	11/1992	WIPO .

[73] Assignees: **Senju Pharmaceutical Co., Ltd.**; **Yoshitomi Pharmaceutical Industries, Ltd.**, both of Osaka, Japan

### OTHER PUBLICATIONS

[21] Appl. No.: **779,604**

Patent Abstracts of Japan, unexamined applications, C field, vol. 10, No. 318, Oct. 29, 1986, p. 140 C 381 of JP-A-61 130 222.

[22] Filed: **Jan. 7, 1997**

Chemical Abstracts, vol. 118, 1993 No. 118:66887f (Abstract of Reference AD).

Chemical Abstracts, vol. 105, 1986, No. 105: 158837z.

### Related U.S. Application Data

[62] Division of Ser. No. 404,102, Mar. 14, 1995.

*Primary Examiner*—José G. Dees

*Assistant Examiner*—Michael A. Williamson

*Attorney, Agent, or Firm*—Wenderoth, Lind & Ponack, L.L.P.

### [30] Foreign Application Priority Data

Mar. 15, 1994 [JP] Japan ..... 6-044184

[51] **Int. Cl.<sup>6</sup>** ..... **A61K 31/44**

[52] **U.S. Cl.** ..... **514/350**; 514/912; 514/913; 514/914; 514/915

[58] **Field of Search** ..... 514/350, 912, 514/913, 914, 915

### [56] References Cited

#### U.S. PATENT DOCUMENTS

4,525,348	6/1985	Arizono et al. ....	424/81
4,607,038	8/1986	Ogata et al. ....	514/291
5,110,493	5/1992	Cherng-Chyi et al. ....	514/413
5,414,011	5/1995	Fu et al. ....	514/413
5,693,337	12/1997	Suzuki et al. ....	424/450

### [57] ABSTRACT

A method for stabilizing pranopfen, comprising placing an aqueous solution of pranopfen in coexistence with an antioxidant, or placing an aqueous solution of pranopfen under the conditions of limited supply of oxygen, and a stable aqueous preparation of pranopfen, comprising pranopfen and an antioxidant. According to the present invention, the decomposition of pranopfen in an aqueous solution of pranopfen is remarkably suppressed. In particular, pranopfen becomes stable to light, thus permitting long-term preservation of an aqueous solution, specifically a liquid preparation, of pranopfen.

**13 Claims, No Drawings**

**METHOD FOR STABILIZING  
PRANOPROFEN AND STABLE LIQUID  
PREPARATION OF PRANOPROFEN**

This is a divisional application of Ser. No. 08/404,102, filed Mar. 14, 1995.

**BACKGROUND OF THE INVENTION**

**1. Field of the Invention**

The present invention relates to a method for stabilizing pranopfen having anti-inflammatory activity, in an aqueous solution of pranopfen, and to a liquid preparation comprising, as an active ingredient, pranopfen which is stabilized by adding an antioxidant.

**2. Description of Related Art**

Pranopfen having a chemical name of  $\alpha$ -methyl-5H-[1]benzopyrano[2,3-b]pyridine-7-acetic acid exhibits prominent anti-inflammatory action, analgesic action and antipyretic action. It is a non-steroidal anti-inflammatory drug having a wider safety margin, and is commercially available by the product name of Niflan (trademark). The properties and production method thereof are described in U.S. Pat. No. 3,931,295.

There has also been proposed an eye drop containing pranopfen as an anti-inflammatory active ingredient and boric acid as an isotonicizing agent, as being useful for, in particular, herpesvirus eye diseases (U.S. Pat. No. 4,607,038).

However, pranopfen is unstable in an aqueous solution state, particularly to light and is gradually decomposed during long-term preservation.

It is therefore an object of the present invention to provide a method for stabilizing pranopfen in an aqueous solution state.

Another object of the present invention is to provide an aqueous solution of pranopfen, wherein decomposition of pranopfen is suppressed.

**SUMMARY OF THE INVENTION**

According to the present invention, it has now been found that decomposition of pranopfen can be markedly suppressed by placing an aqueous solution of pranopfen in coexistence with an antioxidant, or placing an aqueous solution of pranopfen under the conditions of limited supply of oxygen.

That is, the present invention and preferable modes thereof are as follows.

- (1) A method for stabilizing pranopfen, comprising placing an aqueous solution of pranopfen in coexistence with an antioxidant.
- (2) A method for stabilizing pranopfen according to (1), comprising adding an antioxidant to an aqueous solution of pranopfen.
- (3) A method for stabilizing pranopfen according to (2), comprising adding an antioxidant at a ratio to pranopfen of 0.0002–5.0 by weight.
- (4) A method for stabilizing pranopfen according to (1), comprising sealing an aqueous solution of pranopfen in a container formed from a material comprising an antioxidant.
- (5) A method for stabilizing pranopfen according to (4), comprising adding an antioxidant to a material of the container at a ratio to the material of 0.0001–0.005 by weight.
- (6) A method for stabilizing pranopfen according to (4), wherein the container is made of polypropylene.

- (7) A method for stabilizing pranopfen according to (2), wherein the antioxidant is at least one compound selected from the group consisting of alkylphenols, benzopyran derivatives, sodium thiosulfate and amino acids.
- (8) A method for stabilizing pranopfen according to (7), wherein the alkylphenol is at least one compound selected from the group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
- (9) A method for stabilizing pranopfen according to (7), wherein the benzopyran derivative is at least one member selected from the group consisting of L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate] and salts thereof.
- (10) A method for stabilizing pranopfen according to (7), wherein the amino acid is at least one member selected from the group consisting of methionine, tryptophan and histidine.
- (11) A method for stabilizing pranopfen according to any one of (4)–(6), wherein the antioxidant is at least one alkylphenol.
- (12) A method for stabilizing pranopfen according to (11), wherein the alkylphenol is at least one member selected from the group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
- (13) A method for stabilizing pranopfen, comprising placing an aqueous solution of pranopfen under the conditions of limited supply of oxygen.
- (14) A method for stabilizing pranopfen according to (13), comprising sealing a container, in which an aqueous solution of pranopfen has been sealed, in a container or enclosing the container with a sheet, together with a deoxygenating agent.
- (15) A method for stabilizing pranopfen according to (13), comprising sealing an aqueous solution of pranopfen in a container having a low oxygen permeability or enclosing the solution with a sheet having a low oxygen permeability.
- (16) A stabilizing method according to (1), wherein the aqueous solution of pranopfen is an eye drop or a collunarium.
- (17) A stabilizing method according to (13), wherein the aqueous solution of pranopfen is an eye drop or a collunarium.
- (18) A stable liquid preparation of pranopfen, comprising pranopfen and an antioxidant.
- (19) The liquid preparation of (18), wherein the antioxidant is at least one compound selected from the group consisting of alkylphenols, benzopyran derivatives, sodium thiosulfate and amino acids.
- (20) The liquid preparation of (19), wherein the alkylphenol is at least one member selected from the group consisting of dibutylhydroxytoluene and butylhydroxyanisole.
- (21) The liquid preparation of (19), wherein the benzopyran derivative is at least one compound selected from the group consisting of L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate] and salts thereof.
- (22) The liquid preparation of (19), wherein the amino acid is at least one member selected from the group consisting of methionine, tryptophan and histidine.
- (23) The liquid preparation of (18), comprising an antioxidant at a ratio to pranopfen of 0.0002–5.0 by weight.
- (24) The liquid preparation of (18), which is an eye drop.
- (25) The liquid preparation of (18), which is a collunarium.

**DETAILED DESCRIPTION OF THE  
INVENTION**

The first mode of the stabilizing method of the present invention is placing an aqueous solution of pranopfen in

coexistence with an antioxidant, which is realized by, for example, (i) adding an antioxidant to an aqueous solution of pranoprofen (Mode I) or (ii) sealing an aqueous solution of pranoprofen in a container formed from a material comprising an antioxidant (Mode II). The Modes I and II may be used in combination.

The antioxidant to be used in Mode I includes, for example, alkylphenols, benzopyran derivatives, sodium thiosulfate and amino acids.

Examples of alkylphenol include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), n-propyl gallate and catechol, with preference given to BHT and BHA.

Examples of benzopyran derivative include tocopherol, tocol, L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate] and salts thereof, with preference given to L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate] potassium salt (EPC-K<sub>1</sub>).

Amino acid is, for example, methionine, tryptophan or histidine, with preference given to methionine and tryptophan.

When an antioxidant is added to an aqueous solution of pranoprofen according to Mode I, the antioxidant is generally added at a ratio to pranoprofen of 0.0002–5.0 by weight, preferably 0.002–2.5 by weight.

When an aqueous solution of pranoprofen is sealed in a container formed from a material comprising an antioxidant, according to Mode II, the container is, for example, generally a plastic container such as the one composed of polyolefin [e.g. polyethylene (PE) and polypropylene (PP)], with preference given to the one composed of PP.

An antioxidant is added to the material of the container at a ratio to the material of, for example, 0.0001–0.005 by weight, preferably 0.0005–0.005 by weight.

In the Mode II, the antioxidant to be used is, for example, a phenol such as alkylphenol, alkylphenol or thiobisalkylphenol.

Examples of alkylphenol include dibutylhydroxytoluene (BHT), butylhydroxyanisole (BHA), n-propyl gallate, stearyl β-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate, tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyloxymethyl]methane, 1,3,5-tris(3,5-di-tert-butyl-4-hydroxybenzyl)-1H,2H,3H-triazine-2,4,6-trione, 1,3,5-tris[(3,5-di-tert-butyl-4-hydroxybenzyl)-2,4,6-trimethyl]benzene and 3,9-bis[2-(3-(3-tert-butyl-4-hydroxy-5-methylphenyl)propionyloxy)-1,1-dimethylethyl]-2,4,8,10-tetraoxaspiro[5.5]undecane, with preference given to BHT and BHA.

Examples of alkylphenol include 2,2'-methylenebis(4-methyl-6-tert-butylphenol), 4,4'-butylidenebis(2-tert-butyl-5-methylphenol) and 2-tert-butyl-6-(3-tert-butyl-2-hydroxy-5-methylbenzyl)-4-methylphenyl acrylate.

Examples of thiobisalkylphenol include 4,4'-thiobis(2-tert-butyl-5-methylphenol).

The second mode of the stabilizing method of the present invention is placing an aqueous solution of pranoprofen under the conditions of limited oxygen supply. For example, a container containing an aqueous solution of pranoprofen sealed therein is sealed in another container or enclosed with a sheet in coexistence with a deoxygenating agent (Mode III), or an aqueous solution of pranoprofen is sealed in a container having a low oxygen permeability, or enclosed with a sheet having a low oxygen permeability (Mode IV).

In the Mode III, the container for sealing an aqueous solution of pranoprofen is subject to no particular limitation

as long as it can seal an aqueous solution of pranoprofen, and is preferably exemplified by a container formed from a material containing an antioxidant, such as those exemplified for the above-mentioned Mode II, and a container having a low oxygen permeability to be mentioned below.

The deoxygenating agent to be used in Mode III is exemplified by iron powder, iron oxide, ascorbic acid and catechol, with preference given to iron oxide. The deoxygenating agent is preferably packed in a bag etc. made of an oxygen-permeable material and put to use.

The container and the sheet to enclose a container, in which an aqueous solution of pranoprofen has been sealed, together with a deoxygenating agent according to Mode III, are not subject to any particular limitation as long as they can enclose both the container, in which an aqueous solution of pranoprofen has been sealed, and a deoxygenating agent in such a manner that the outside air is shut off from them. Examples of the container include plastic containers and glass containers, and examples of the sheet include plastic sheets and aluminum sheets. The materials for such containers and sheets may contain an antioxidant, as exemplified in the above-mentioned Mode II, or may have a low oxygen permeability as discussed below. Also, an antioxidant may be added to an aqueous solution of pranoprofen in Mode III.

The container and the sheet having low oxygen permeability, which are to be used in Mode IV, are preferably made from a material having an oxygen permeability of not more than 120 cc/m<sup>2</sup>·24 hr·atom [20° C.·90% relative humidity (RH), thickness of material 25 μm], preferably not more than 70 cc/m<sup>2</sup>·24 hr·atom (20° C.·90% RH, thickness of material 25 μm), such as those made from acrylonitrile resins [e.g. acrylonitrile styrene (AS) and acrylonitrile butadiene styrene (ABS)] and polyethylene terephthalate (PET), with particular preference given to those made from PET.

The solvent to be used to prepare a liquid preparation and an aqueous solution of pranoprofen of the present invention is exemplified by sterile purified water, in particular, distilled water for injection. The concentration of the active ingredient pranoprofen is generally 0.01–2.0 w/v %, preferably 0.05–1.0 w/v %, which is increased or decreased as appropriate according to the object of use.

The antioxidant to be used for the liquid preparation of pranoprofen of the present invention is exemplified by those mentioned for Mode I.

The liquid preparation of the present invention may further contain various additives on demand, such as buffers, isotonicizing agents, solubilizing agents, preservatives, thickeners, chelating agents, pH adjusting agents and aromatic agents.

Examples of buffer include phosphate buffer (e.g. sodium dihydrogenphosphate-disodium hydrogenphosphate and potassium dihydrogenphosphate-potassium hydroxide), borate buffer (e.g. boric acid-sodium tetraborate), citrate buffer (e.g. sodium citrate-sodium hydroxide), tartrate buffer (e.g. tartaric acid-sodium tartrate), acetate buffer (e.g. acetic acid-sodium acetate), carbonate buffer (e.g. sodium carbonate-citric acid and sodium carbonate-boric acid) and amino acid (e.g. sodium glutamate and ε-aminocaproic acid).

When the liquid preparation of pranoprofen is used as an eye drop, it is preferable that borate buffer, acetate buffer or carbonate buffer be used to decrease irritation.

Examples of isotonicizing agent include saccharides such as sorbitol, glucose and mannitol, polyhydric alcohols such as glycerol and propylene glycol, salts such as sodium chloride and sodium tetraborate, and boric acid.

Examples of solubilizing agent include non-ionic surfactants such as polyoxyethylenesorbitan monooleate (polysorbate 80), polyoxyethylenemonostearate, polyethylene glycol and polyoxyethylene hydrogenated castor oil.

Examples of preservative include quaternary ammonium salts such as benzalkonium chloride, benzethonium chloride and cetylpyridinium chloride, p-hydroxybenzoates such as methyl p-hydroxybenzoate, ethyl p-hydroxybenzoate, propyl p-hydroxybenzoate and butyl p-hydroxybenzoate, benzyl alcohol, phenetyl alcohol, sorbic acid and salts thereof, thimerosal, chlorobutanol and sodium dehydroacetate.

Examples of thickener include polyvinylpyrrolidone, hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose and salts thereof.

Examples of chelating agent include disodium edetate and citric acid.

Examples of pH-adjusting agent include hydrochloric acid, citric acid, phosphoric acid, acetic acid, tartaric acid, sodium hydroxide, potassium hydroxide, sodium carbonate and sodium hydrogencarbonate.

Examples of aromatic agent include 1-menthol, borneol, camphor (e.g. dl-camphor) and eucalyptus oil.

The liquid preparation of the present invention is used as an eye drop, collunarium and the like. When used as an eye drop, its pH is generally adjusted to about 6.0–8.5, preferably about 7.0–8.0, and when used as a collunarium, its pH is generally adjusted to about 6.0–8.5, preferably about 7.0–8.0.

While the method for producing the liquid preparation of the present invention varies depending on the kind of liquid preparation, a known method for each liquid preparation can be used.

The dose of the liquid preparation of the present invention, when used, for example, as an eye drop, is an amount sufficient to effectively resolve ophthalmic inflammation, and varies depending on symptoms and the kind of inflammation. The dose is generally 5.0–1,000  $\mu\text{g}$ /administration, preferably 25–500  $\mu\text{g}$ /administration, which is administered 2 to 5 times a day as appropriate.

The present invention is described in more detail in the following by referring to Experimental Examples and Examples.

#### EXPERIMENTAL EXAMPLE 1

##### [Stability Test—No. 1]

A solution of 0.1 w/v % pranoprofen [boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount] was filled in 5 ml polypropylene containers manufactured by adding BHT to 0.05, 0.1 or 0.5 w/v % [oxygen permeability of 25  $\mu\text{m}$  thick test sample, 3,800  $\text{cc}/\text{m}^2\cdot 24$  hr-atom (20° C.·90% RH); Gas Permeation Test Method of Plastic Film and Sheet of Japanese Industrial Standards, the equal pressure method [Japanese Standards Association, JIS Handbook, p 400, Tokyo (1991)]] and 15 ml polyethylene terephthalate containers [oxygen permeability of 25  $\mu\text{m}$  thick test samples, 63  $\text{cc}/\text{m}^2\cdot 24$  hr-atom (20° C.·90% RH); Gas Permeation Test Method of Plastic Film and Sheet of Japanese Industrial Standards, the equal pressure method [Japanese Standards Association, JIS Handbook, p 400, Tokyo (1991)]]], and left standing in the dark at room temperature for 36 months. The residual content of prano-

profen in the containers was determined with time by high performance liquid chromatography. The results are shown in Table 1.

TABLE 1

Container	Residual content of pranoprofen (%)					
	On preparation	3 months	6 months	12 months	24 months	36 months
PP (control)	100.0	95.6	93.9	—	81.9	78.5
PP-05	100.0	100.4	99.3	99.0	98.5	100.2
PP-01	100.0	100.4	98.3	98.1	95.4	96.0
PP-005	100.0	100.4	98.3	97.0	93.2	93.3
PET	100.0	99.5	101.0	100.3	100.8	99.4

PP: polypropylene container without BHT oxygen permeability, 3800  $\text{cc}/\text{m}^2\cdot 24$  hr · atom (20° C. · 90% RH, 25  $\mu\text{m}$ )  
 PP-05: polypropylene container containing 0.5% BHT  
 PP-01: polypropylene container containing 0.1% BHT  
 PP-005: polypropylene container containing 0.05% BHT  
 PET: polyethylene terephthalate container without BHT oxygen permeability, 63  $\text{cc}/\text{m}^2\cdot 24$  hr · atom (20° C. · 90% RH, 25  $\mu\text{m}$ )

As is evident from Table 1, superior suppression of decomposition of pranoprofen was achieved by preserving pranoprofen in the containers (PP) formed from a material containing BHT and in the container (PET) having a low oxygen permeability.

#### EXPERIMENTAL EXAMPLE 2

##### [Stability Test—No. 2]

BHT or sodium thiosulfate was added to a basic formulation solution [pranoprofen, 0.1 w/v %; boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount], and the mixture was filled in 5 ml polypropylene containers. The containers were left standing in the dark at room temperature for 39 months. The residual content of pranoprofen in the containers was determined by high performance liquid chromatography. The results are shown in Table 2.

TABLE 2

Compound	Concentration (%)	Residual content of pranoprofen (%)	
		On preparation	after 39 months
Control (not added)	0	100.0	77.0
BHT	0.0004	100.0	99.6
"	0.0001	100.0	94.7
sodium thiosulfate	0.1	100.0	93.0

As is evident from Table 2, superior suppression of decomposition of pranoprofen was achieved by the addition of respective antioxidants.

#### EXPERIMENTAL EXAMPLE 3

##### [Stability Test—No. 3]

BHT, BHA, L-ascorbic acid 2-[3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl-hydrogen phosphate] potassium salt (EPC-K<sub>1</sub>), methionine, tryptophan or histidine was added to a basic formulation solution [pranoprofen, 0.05 w/v %; boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005

w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount], and the mixture was filled in colorless 15 ml polyethylene terephthalate containers. The containers were left standing under a fluorescent lamp (20 W). When the total irradiation reached 100,000 lux·hr, the residual content of pranoprofen in the containers was determined by high performance liquid chromatography. The results are shown in Table 3.

TABLE 3

Compound added	Concentration (%)	Residual content of pranoprofen (%)	
		On preparation	after irradiation of 100,000 lux · hr
Control (not added)	0	100.0	52.5
BHT	0.005	100.0	98.0
"	0.002	100.0	96.6
"	0.0002	100.0	70.8
BHA	0.002	100.0	92.8
EPC-K <sub>1</sub>	0.05	100.0	79.1
"	0.01	100.0	70.5
"	0.001	100.0	68.2
methionine	0.24	100.0	95.2
tryptophan	0.06	100.0	96.9
histidine	0.13	100.0	75.9

As is evident from Table 3, the decomposition of pranoprofen caused by the exposure to the light was markedly suppressed by the addition of respective antioxidants.

## EXPERIMENTAL EXAMPLE 4

## [Stability Test—No. 4]

A solution of 0.1 w/v % pranoprofen [boric acid, 1.6 w/v %; sodium tetraborate, appropriate amount; disodium edetate, 0.01 w/v %; benzalkonium chloride, 0.005 w/v %; polysorbate 80, 0.1 w/v %; sterile purified water, appropriate amount] was filled in 5 ml polypropylene containers and the containers were tightly sealed. The containers were enclosed together with iron oxide (Ageless Z-30, manufactured by Mitsubishi Gas Chemical Company, Inc.) as a deoxygenating agent, with the use of a multi-layer film of polypropylene/poly(vinyl alcohol)/polyethylene and left standing at room temperature for 30 months. The residual content of pranoprofen in the containers was determined with time by high performance liquid chromatography. The results are shown in Table 4.

TABLE 4

Enclosing	Residual content of pranoprofen (%)				
	On preparation	2 months	6 months	9 months	30 months
Unenclosed	100.0	95.1	89.4	92.0	80.3
Film-enclosed (deoxygenator)	100.0	98.1	97.6	97.2	101.0
Film-enclosed (N <sub>2</sub> substitution)	100.0	95.0	93.4	89.5	88.5

Containers used: polypropylene containers without BHT  
 Film: multi-layer film of polypropylene/poly(vinyl alcohol)/polyethylene  
 deoxygenating agent: iron oxide (Ageless Z-30, manufactured by Mitsubishi Gas Chemical Company, Inc.)

As is evident from Table 4, marked suppression of decomposition of pranoprofen was achieved by sealing a container, in which an aqueous solution of pranoprofen had been

sealed, together with a deoxygenating agent.

## Example 1 [Eye drop]

(1)	Pranoprofen	0.2 g
(2)	Disodium hydrogenphosphate	0.5 g
(3)	Sodium dihydrogenphosphate	0.1 g
(4)	Polyoxyethylene hydrogenated castor oil 60	0.1 g
(5)	Poly(vinyl alcohol)	0.2 g
(6)	Sodium chloride	0.8 g
(7)	Benzethonium chloride	0.007 g
(8)	BHT	0.01 g
(9)	Sodium hydroxide	appropriate amount
(10)	Sterile purified water	appropriate amount
Total		100 ml

(5) was added to about 70 ml of (10) and the mixture was stirred with heating to about 70° C. for dissolution. (4) and (8) were added to this solution and the mixture was admixed until it became a uniform dispersion. The mixture was cooled to room temperature. (1), (2), (3), (6) and (7) were dissolved in this solution and pH was adjusted to 7.2 with (9). (10) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PE container for an eye drop.

## Example 2 [Eye drop]

(1)	Pranoprofen	0.4 g
(2)	Sodium chloride	0.5 g
(3)	Polysorbate 80	0.15 g
(4)	Polyethylene glycol	0.5 g
(5)	Citric acid	0.2 g
(6)	Benzalkonium chloride	0.009 g
(7)	Sodium thiosulfate	0.01 g
(8)	Sodium carbonate	appropriate amount
(9)	Sterile purified water	appropriate amount
Total		100 ml

(1), (2), (3), (4), (5), (6) and (7) were dissolved in about 70 ml of (9) and pH was adjusted to 8.0 with (8). (9) was added to make the total amount 100 ml and the mixture was filled in a 5 ml PP container for an eye drop.

## Example 3 [Eye drop]

(1)	Pranoprofen	0.1 g
(2)	Potassium dihydrogenphosphate	0.3 g
(3)	Conc. glycerol	2.6 g
(4)	Potassium hydroxide	appropriate amount
(5)	Disodium edetate	0.01 g
(6)	EPC-K <sub>1</sub>	0.05 g
(7)	Methyl p-hydroxybenzoate	0.026 g
(8)	Propyl p-hydroxybenzoate	0.014 g
(9)	Sterile purified water	appropriate amount
Total		100 ml

About 80 ml of (9) was heated to about 90° C. and (7) and (8) were dissolved. The mixture was cooled to room temperature. An appropriate amount of (4) was dissolved and then, (1), (2), (3), (5) and (6) were dissolved. Its pH was adjusted to 6.5 with (4). (9) was added to make the total amount 100 ml and the mixture was filled in a 10 ml polycarbonate container for an eye drop.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.